CTOs on the Move

Landos Biopharma

www.landosbiopharma.com

 
Landos pursues safer, more effective first-in-class oral therapeutics for autoimmune disorders at an accelerated rate.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Landos Biopharma raised $10M on 09/21/2017

Similar Companies

Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

Privee Clinics

Privée Clinics is a state-of-the-art facility that utilizes the latest and most innovative cutting edge technology in the industry of mental and physical

PolyPeptide Group

PolyPeptide Labs is a world leader in the manufacture of polypeptide, custom peptide Synthesis, peptide synthesis and generic peptide : generic GMP peptide and non-GMP peptide. PolyPeptide provides global support for a quality solution.

Pro Med Pharmacies

Pro Med Pharmacies, Inc is a Amarillo, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UroGen

UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.